GO:0048407 platelet-derived growth factor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0048407 (platelet-derived growth factor binding) is a molecular function defined as binding to platelet-derived growth factor (PDGF).
• PDGF binding is the first step in PDGF signaling and is mediated by high-affinity cell-surface receptors and soluble binding proteins.
• The PDGF family includes disulfide-linked dimers such as PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD, which bind with different affinities to PDGF receptors.
• PDGF binding controls chemotaxis, proliferation, survival, and angiogenesis in many cell types.
• Dysregulated PDGF binding contributes to cancers, fibrosis, and vascular disease, making it a target for experimental models.
• CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of PDGF-binding proteins in disease.
Description
Platelet-derived growth factor binding (GO:0048407) is a molecular function that describes the selective interaction of a protein or protein complex with platelet-derived growth factor (PDGF). PDGF was originally identified as a mitogen in serum and later shown to bind specific target cells with high affinity. This binding event is the initiating step for a broad signaling network that regulates cell proliferation, migration, and survival. Because PDGF binding is a molecular recognition event, it is studied at the level of receptor-ligand interactions, soluble binding proteins, and extracellular matrix-associated factors. The importance of GO:0048407 extends beyond basic cell biology. PDGF binding is central to developmental processes, wound healing, and angiogenesis, and its dysregulation is implicated in cancer, fibrosis, and vascular disorders. For example, PDGF cross-signaling through non-corresponding receptors has been observed in colorectal cancer, indicating that binding specificity can be bypassed in disease. In cholangiocarcinoma, PDGF-D produced by tumor cells acts on cancer-associated fibroblasts, highlighting the role of PDGF binding in the tumor microenvironment. Researchers studying GO:0048407 need reliable experimental systems to test which proteins bind PDGF, how binding affinity is regulated, and what downstream effects follow. This article summarizes the authoritative definition, the major genes and proteins involved, disease links, and the CRISPR-based methods used to dissect PDGF binding in human cells.
platelet-derived growth factor binding At A Glance
| GO ID | GO:0048407 |
|---|---|
| GO term | platelet-derived growth factor binding |
| Ontology | molecular_function |
| Synonym | PDGF binding |
| Definition | Binding to platelet-derived growth factor. |
| Major function | Mediates the initial recognition of PDGF ligands by receptors and binding proteins. |
| Related ligands | PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, PDGF-DD. |
| Major receptor family | PDGF receptors (PDGFR-alpha and PDGFR-beta). |
| Cellular context | Cell surface, extracellular matrix, and secreted soluble factors. |
What Is GO:0048407?
GO:0048407, platelet-derived growth factor binding, is defined as the binding to platelet-derived growth factor. In practical terms, it is the molecular function of any protein that physically interacts with a PDGF ligand, including cell-surface receptors, soluble carrier proteins, and matrix-associated molecules. This function is distinct from downstream signaling events; it specifically describes the recognition and interaction with PDGF.
Why Is platelet-derived growth factor binding Important in Cell Biology?
GO:0048407 is important because PDGF binding is the first committed step in a signaling axis that controls fundamental cell behaviors such as proliferation, chemotaxis, and survival. Alterations in PDGF binding affinity or specificity can rewire signaling networks in cancer and fibrosis, making this function a focal point for both mechanistic studies and therapeutic targeting.
• PDGF binding initiates receptor dimerization and activation, which drives cell cycle progression and migration.
• It is essential for chemotaxis of mesenchymal cells, fibroblasts, and smooth muscle cells.
• PDGF-D binding promotes angiogenic capacity of endothelial progenitor cells.
• Alternative splicing of PDGF A-chain generates isoforms with different binding properties and secretion fates.
• PDGF binding cross-talk with non-corresponding receptors can bypass normal signaling constraints in colorectal cancer.
• In cholangiocarcinoma, PDGF-D binding to cancer-associated fibroblasts supports a pro-tumorigenic microenvironment.
• High-affinity binding sites for PDGF were among the first demonstrated on target cells, establishing the paradigm of growth factor binding.
• Dysregulated PDGF binding is associated with atherosclerosis, fibrotic diseases, and multiple malignancies.
• Understanding PDGF binding specificity informs the design of receptor-blocking biologics and small molecules.
• CRISPR-based models enable causal testing of PDGF-binding proteins in human disease contexts.
Molecular Mechanism of platelet-derived growth factor binding
Ligand recognition and binding specificity
In simple terms: PDGF binding starts when a PDGF protein docks onto a receptor or binding protein on the cell surface.
PDGF ligands are disulfide-linked dimers that present distinct surfaces for receptor engagement. The binding specificity of PDGF isoforms (AA, AB, BB, CC, DD) for PDGF receptors alpha and beta determines which cells respond. High-affinity binding sites on target cells were demonstrated early using radiolabeled PDGF, establishing the concept of specific receptor-ligand recognition. Alternative splicing of the PDGF A-chain produces isoforms that differ in their binding and secretion properties, further diversifying the binding landscape.
Receptor dimerization and activation
In simple terms: Once PDGF binds, two receptor molecules come together and switch on signaling.
Binding of PDGF to its receptors induces receptor dimerization, which activates intrinsic tyrosine kinase activity and autophosphorylation. This activation creates docking sites for downstream signaling proteins, linking PDGF binding to intracellular pathways that control proliferation and migration. The mechanism of PDGF-induced chemotaxis specifically requires receptor activation and polarized signaling.
Soluble and matrix-associated PDGF binding proteins
In simple terms: Not all PDGF binding happens on the cell surface; some proteins in blood or the matrix also bind PDGF.
In addition to cell-surface receptors, soluble proteins such as alpha-2-macroglobulin can bind PDGF and modulate its availability. Extracellular matrix components can sequester PDGF, creating local reservoirs that influence binding to receptors. These interactions fine-tune the spatial and temporal distribution of PDGF, affecting which cells receive the signal.
Cross-signaling and bypass mechanisms
In simple terms: Sometimes PDGF can bind to receptors it normally would not, leading to unexpected signaling.
In colorectal cancer, PDGF cross-signaling via non-corresponding receptors indicates that binding specificity can be bypassed, leading to alternative downstream outputs. This bypass mechanism may contribute to resistance to therapies targeting canonical PDGF receptors. Such findings highlight the need to study PDGF binding in disease-specific contexts rather than assuming normal rules apply.
Regulation of PDGF binding availability
In simple terms: The amount of PDGF available to bind is controlled by production, secretion, and degradation.
PDGF binding is regulated by the expression levels of ligands and receptors, alternative splicing, and the presence of binding proteins that compete or cooperate. In the tumor microenvironment, cancer cells and stromal cells exchange PDGF signals, as seen in cholangiocarcinoma where PDGF-D from tumor cells acts on cancer-associated fibroblasts. This cross-talk modulates the effective concentration of PDGF available for binding to receptors on target cells.
Key Genes Involved in GO:0048407 platelet-derived growth factor binding
The following genes and proteins are central to platelet-derived growth factor binding (GO:0048407), based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PDGFA | Encodes PDGF A-chain; forms PDGF-AA and PDGF-AB dimers that bind PDGF receptors. | Alternative splicing produces isoforms with different binding and secretion properties. |
| PDGFB | Encodes PDGF B-chain; forms PDGF-BB, a potent mitogen that binds PDGFR-beta. | Widely studied in fibrosis and vascular disease. |
| PDGFC | Encodes PDGF C-chain; forms PDGF-CC, which binds PDGFR-alpha. | Implicated in angiogenesis and tissue remodeling. |
| PDGFD | Encodes PDGF D-chain; forms PDGF-DD, which binds PDGFR-beta. | Promotes angiogenic capacity of endothelial progenitor cells; involved in cholangiocarcinoma cross-talk. |
| PDGFRA | Encodes PDGFR-alpha, a receptor tyrosine kinase that binds PDGF-AA, -AB, -BB, and -CC. | Target for mutation and overexpression studies in cancer. |
| PDGFRB | Encodes PDGFR-beta, a receptor tyrosine kinase that binds PDGF-BB and -DD. | Key mediator of chemotaxis and proliferation. |
| A2M | Alpha-2-macroglobulin binds PDGF in plasma, modulating its availability. | Studied as a soluble PDGF-binding protein. |
| SPARC | Secreted protein acidic and rich in cysteine can bind PDGF and affect its interaction with receptors. | Matrix-associated regulator of PDGF binding. |
| COL1A1 | Type I collagen can sequester PDGF in the extracellular matrix. | Matrix binding influences local PDGF concentration. |
| COL3A1 | Type III collagen interacts with PDGF and modulates its bioavailability. | Relevant to fibrosis and matrix remodeling. |
| FN1 | Fibronectin binds PDGF and affects its presentation to cells. | Studied in wound healing and cancer. |
| LRP1 | Low-density lipoprotein receptor-related protein 1 binds PDGF and mediates its clearance. | Regulates PDGF levels in tissues. |
| HSPG2 | Perlecan, a heparan sulfate proteoglycan, binds PDGF and modulates receptor binding. | Matrix co-receptor for PDGF. |
| SDC1 | Syndecan-1 can bind PDGF and influence signaling. | Cell-surface proteoglycan in PDGF binding. |
| ITGB1 | Integrin beta-1 cooperates with PDGF binding to regulate cell adhesion and migration. | Cross-talk between integrins and PDGF receptors. |
| PTK2 | Focal adhesion kinase (FAK) is activated downstream of PDGF binding and regulates chemotaxis. | Effector of PDGF-induced migration. |
| SRC | SRC family kinases are activated by PDGF binding and contribute to proliferation. | Downstream mediator of PDGF signaling. |
| PIK3CA | PI3K catalytic subunit is recruited after PDGF binding and controls survival. | Key downstream pathway. |
How Is platelet-derived growth factor binding Regulated?
PDGF binding is regulated at multiple levels. Ligand availability is controlled by expression, alternative splicing, and secretion. Soluble binding proteins such as alpha-2-macroglobulin and matrix components like collagens and proteoglycans can sequester PDGF, reducing its effective concentration. Receptor levels and post-translational modifications also modulate binding capacity. In disease, cross-signaling through non-corresponding receptors can bypass normal regulatory constraints, as seen in colorectal cancer. In the tumor microenvironment, cancer-associated fibroblasts and tumor cells exchange PDGF signals that alter binding dynamics.
platelet-derived growth factor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PDGFD | Cholangiocarcinoma cross-talk with cancer-associated fibroblasts | Knockout of PDGFD in cholangiocarcinoma cells co-cultured with fibroblasts |
| PDGFRB | Colorectal cancer bypass signaling | Point mutation of PDGFRB to test ligand-independent activation |
| PDGFRA | Fibrosis and vascular disease | Overexpression of PDGFRA in primary fibroblasts |
| PDGFA | Alternative splicing in cancer | Knock-in of specific splice isoforms |
| A2M | PDGF sequestration in plasma | Knockout of A2M in hepatocytes to study PDGF availability |
Cancer
Dysregulated PDGF binding is a hallmark of several cancers. In colorectal cancer, PDGF cross-signaling via non-corresponding receptors indicates bypassed signaling, which may drive tumor growth and resistance. In cholangiocarcinoma, PDGF-D produced by cancer cells binds to cancer-associated fibroblasts, promoting a pro-tumorigenic microenvironment. These examples show that PDGF binding specificity and cross-talk are critical determinants of cancer biology.
Fibrosis and vascular disease
PDGF binding is a potent driver of fibroblast proliferation and migration, contributing to fibrotic diseases in lung, liver, and kidney. In vascular disease, PDGF binding promotes smooth muscle cell migration and intimal hyperplasia. The chemotactic response to PDGF is a key mechanism in these pathologies.
Angiogenesis and tissue repair
PDGF-D binding enhances the angiogenic capacity of endothelial progenitor cells, linking PDGF binding to blood vessel formation. This function is important in wound healing and ischemia, but can also support tumor angiogenesis. Understanding how PDGF binding regulates angiogenesis may inform regenerative and anti-angiogenic strategies.
From platelet-derived growth factor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PDGFD reduce angiogenic capacity? | PDGFD knockout endothelial progenitor cells |
| Can PDGFRB mutations cause ligand-independent signaling? | Point-mutation knock-in of PDGFRB in colorectal cancer cells |
| Which PDGF isoforms bind PDGFR-alpha versus beta? | Competitive binding assays with tagged PDGF ligands |
| Does matrix binding of PDGF affect chemotaxis? | Knockout of matrix proteins (e.g., COL1A1) in fibroblast models |
| Does PDGF-D from tumor cells activate fibroblasts? | Co-culture of PDGFD knockout cholangiocarcinoma cells with fibroblasts |
| How does alternative splicing of PDGFA affect binding? | Knock-in of specific PDGFA splice variants |
How to Study the platelet-derived growth factor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding assay | Binding affinity and receptor number | Characterizing PDGF-receptor interactions |
| CRISPR knockout screen | Genes required for PDGF binding/signaling | Discovery of novel regulators |
| Affinity purification + mass spectrometry | PDGF-interacting proteins | Identifying soluble and matrix binding proteins |
| Live-cell imaging | Binding dynamics and internalization | Real-time visualization of PDGF binding |
| Chemotaxis assay | Directed cell migration in PDGF gradients | Functional readout of PDGF binding |
| Phospho-proteomics | Downstream signaling activation | Mapping pathways activated by PDGF binding |
| Co-culture assays | Paracrine PDGF signaling | Tumor-stroma interactions |
| Splice variant analysis | Isoform-specific binding | Alternative splicing studies |
Receptor binding assays
Radiolabeled or fluorescently labeled PDGF can be used to measure binding affinity and specificity to cells or purified receptors. Competitive binding assays with unlabeled ligands help determine which PDGF isoforms compete for the same binding sites. These methods are foundational for studying GO:0048407.
CRISPR-based genetic screens
Genome-wide CRISPR knockout screens can identify genes required for PDGF binding and downstream signaling. Such screens are useful for discovering novel PDGF-binding proteins or regulators of binding specificity. Hits can be validated with focused knockout or overexpression models.
Proteomics and interactomics
Affinity purification coupled with mass spectrometry can identify proteins that bind PDGF in cell lysates or conditioned media. This approach reveals soluble and matrix-associated PDGF-binding proteins. Proteomic profiling of PDGF-treated cells can also map downstream signaling changes.
Imaging and live-cell assays
Fluorescently tagged PDGF and receptors enable real-time imaging of binding, internalization, and trafficking. Live-cell assays can measure chemotaxis in response to PDGF gradients. These methods provide spatial and temporal resolution of PDGF binding events.
How CRISPR Can Be Used to Study GO:0048407 platelet-derived growth factor binding
Knockout
CRISPR knockout of PDGF ligands or receptors can abolish PDGF binding and reveal its functional consequences. For example, knocking out PDGFD in endothelial progenitor cells reduces angiogenic capacity. Knockout models are essential for causal inference in PDGF binding research.
Point Mutation
Point mutations in PDGF receptors can alter binding affinity or create ligand-independent activation. CRISPR point-mutation knock-in allows precise testing of residues involved in PDGF binding. Such models help dissect binding specificity and downstream signaling.
Knock-in
Knock-in of tagged PDGF or receptor alleles enables visualization and purification of binding complexes. This approach can also be used to express specific splice isoforms of PDGFA to study their binding properties. Knock-in models provide physiological expression levels for accurate binding studies.
Overexpression
Overexpression of PDGF ligands or receptors can amplify binding signals and reveal saturating or gain-of-function phenotypes. This is useful for studying chemotaxis and proliferation in response to PDGF. Overexpression models complement knockout studies by providing opposite perturbations.
How EDITGENE Supports platelet-derived growth factor binding Research
Researchers studying platelet-derived growth factor binding-related genes often need to determine whether a candidate gene is causally involved in PDGF binding, signaling, or disease phenotypes. EDITGENE provides CRISPR-based cell model services to enable such causal studies with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for platelet-derived growth factor binding research.
Frequently Asked Questions About platelet-derived growth factor binding
What is platelet-derived growth factor binding?
Platelet-derived growth factor binding (GO:0048407) is the molecular function of binding to PDGF, a family of disulfide-linked growth factor dimers that regulate cell proliferation, migration, and survival.
What genes are involved in platelet-derived growth factor binding?
Key genes include PDGFA, PDGFB, PDGFC, PDGFD, PDGFRA, PDGFRB, and soluble or matrix proteins such as A2M, SPARC, and collagens.
What is the GO ID for platelet-derived growth factor binding?
The GO ID is GO:0048407, a molecular function term in the Gene Ontology.
How does PDGF binding activate signaling?
PDGF binding induces receptor dimerization and tyrosine kinase activation, leading to downstream pathways that control proliferation and chemotaxis.
Which diseases are linked to PDGF binding?
Dysregulated PDGF binding is linked to cancers such as colorectal cancer and cholangiocarcinoma, as well as fibrosis and vascular disease.
What experimental models are used to study PDGF binding?
Common models include CRISPR knockout, point-mutation knock-in, overexpression cell lines, and co-culture systems.
How is PDGF binding measured?
Binding is measured using radioligand binding assays, live-cell imaging, and affinity purification with mass spectrometry.
What is the role of PDGF-D in angiogenesis?
PDGF-D binding promotes the angiogenic capacity of endothelial progenitor cells.
Can PDGF bind to non-canonical receptors?
Yes, in colorectal cancer PDGF cross-signaling via non-corresponding receptors indicates bypassed signaling.
What is the difference between PDGF binding and PDGF signaling?
PDGF binding (GO:0048407) is the molecular recognition event, while signaling refers to downstream intracellular events after receptor activation.
Conclusion
Platelet-derived growth factor binding (GO:0048407) is a fundamental molecular function that initiates a broad signaling network controlling cell proliferation, migration, and survival. Its dysregulation is implicated in cancer, fibrosis, and vascular disease, making it a key area of biomedical research. CRISPR-based cell models provide powerful tools to dissect the causal roles of PDGF-binding proteins and to identify new therapeutic targets.
References
- 1. Bowen-Pope DF et al.. 1984. Platelet-derived growth factor.. Clin Endocrinol Metab 13(1):191-205 PMID: 6327124
- 2. Moench R et al.. 2022. Platelet-derived growth factor (PDGF) cross-signaling via non-corresponding receptors indicates bypassed signaling in colorectal cancer.. Oncotarget 13:1140-1152 PMID: 36264073
- 3. Zhang J et al.. 2019. Platelet‑derived growth factor D promotes the angiogenic capacity of endothelial progenitor cells.. Mol Med Rep 19(1):125-132 PMID: 30483778
- 4. Huang JS et al.. 1982. Platelet-derived growth factor. Specific binding to target cells.. J Biol Chem 257(14):8130-6 PMID: 6282873
- 5. Rönnstrand L et al.. 2001. Mechanisms of platelet-derived growth factor-induced chemotaxis.. Int J Cancer 91(6):757-62 PMID: 11275976
- 6. Berasain C et al.. 2013. Platelet-derived growth factor D: a new player in the complex cross-talk between cholangiocarcinoma cells and cancer-associated fibroblasts.. Hepatology 58(3):853-5 PMID: 23696149
- 7. Khachigian LM et al.. 1992. Platelet-derived growth factor and alternative splicing: a review.. Pathology 24(4):280-90 PMID: 1289770
- 8. Claesson-Welsh L. 1996. Mechanism of action of platelet-derived growth factor.. Int J Biochem Cell Biol 28(4):373-85 PMID: 9026349
